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In the lightning-paced world of genetic
research, time is ofthe essence. A trio of
NIEHS-based scientists have taken this
adage to heart and recendy reached an
extraordinary milestone, cloning an
entire single gene-the breast cancer
gene BRCA2-in just two weeks'
time. Michael Resnick, a scientist in
the NIEHS Laboratory ofMolecular
Genetics, andVladimir Larionov and I Natasha Kouprina, visiting Russian
scientists from the Institute of
Cytology in St. Petersburg, published
their new method in the 8 July 1997
issue of the Proceedings ofthe National
Academy ofSciences. Last year, the team
pioneered a method called transformation-
associated recombination (TAR) for quickly
cloning fragments of genetic material in yeast
(see EHP104:616-618).
In shaving a months-long process down to
a mere two weeks, the team has also demon-
strated that the clones can be generated with
specificity and selectivity, instead ofrandomly.
Their discovery is asignificant step en route to
mapping the human genome because it will
enable other researchers to fill knowledge gaps
in the genome faster and more accurately than
has ever been possible. Equally important,
however, is the cloning method's significance
for human health: soon, this technique for
rapid-fire recombinational recovery ofhuman
genes may open up new avenues toward gene
therapy and gene discovery. The team's work
has spawned a new gene isolation unit within
the Laboratory of Molecular Genetics, which
will work exclusively to isolate new genes in
the future.
Isolatingthe Gene
Retrieving an exact gene copy so quickly is
remarkable, considering that previous
approaches took up to a year to complete.
Until now, scientists who wanted to isolate and
Running in circles.
In TAR cloning, human DNA is
taken up by a yeast cell along with
linearized vector DNA containing a
centromere and markerfor selection.
If segments of the human DNA correspond to
hooks (A and B) on the plasmid, recombination
will create a circularYAC. Source:VladimirLarionov
clone a gene or chromosomal fragment had to
endure months of tedious analysis, sorting
through a library of millions offragments to
find the exact ones they desired, then proceed
through laborious and time-consuming map-
ping studies. "You had to go back and analyze
every transformant-every done-for whether
you had what you wanted," says Resnick. To
complicate the process even further, overlap-
ping clones sometimes needed to be pieced
together into a larger unit, or "contig," to
achieve the desired done. However, using the
TAR cloning method in yeast, the NIEHS
team decided to targetspecific genes. To do so,
they set out to extract a single gene-roughly
100,000 bases-from the human genome of
3 billion bases. To isolate this single gene,
the team first created a circular plasmid
and linearized it to produce a frag-
ment of DNA with this structure:
BRCA2 promoter sequence (669
base pairs)-centromere-HIS3-
BRCA2 last exon sequence (308
base pairs). They then added this
fragment to total human genomic
DNA, transformed the entire
mixture into the yeast, and select-
ed for HIS3+ cells. Because seg-
ments on the human DNA
matched the promoter and last
exon "hooks" at each end of
the plasmid, the segments
together underwent intra-
cellular recombination
and produced the entire
BRCA2 gene, using
information derived
from only a tiny portion
ofthe gene.
At this point, the
researchers obtained approxi-
mately 1,000 HIS3+ clones and divided
them into 33 pools, which they screened for
BRCA2 sequences by polymerase chain reac-
tions. Their results confirmed that the entire
genewasindeed present.
Larionov admits his initial reaction was
disbelief when the first isolation was com-
plete. "It was so exciting, but I refused to
believe it for one month," he recalls. The
team went on, though, to reproduce the
results 12 times. "Only after that, I started
to believe," Larionov says. And time after
time, molecular analysis showed the quali-
ty of the clones to be very high. Larionov
gives credit for their success in part to the
team's collaboration with NIEHS scientific
director Carl Barrett, whose work led to
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the discovery ofthe BRCA2 gene, as well as
to Gregory Solomon, a researcher in the
NIEHS's Laboratory ofMolecular Carcino-
genesis, which Barrett heads. "Solomon is
an expert in molecular biotechnology; he
helped us select what sequences we should
target," says Larionov.
Sequences andSelectivity
Manyscientists have contributed to the ongo-
ingworkofshaping up the human genome-
work that should easily be completed within
the next 5-10 years. In the past decade,
researchers with the Human Genome Project
have identified unique sequences called
sequence tag sites approximately every 150
kilobytes along the genome, and have also
sequenced short regions of nearly all the
expressed genes producingexpressed sequence
tags. And even though mostofthe chromoso-
mal DNA has been doned, until recently no
one had directly isolated genes that corre-
spond to specific diseases, nor had anyone
directly isolated specific chromosomal regions
fromgenomic DNA.
"We're the only ones who have really
explored the idea ofachieving selectivity,"
Resnick says. "Prior to this, there were no
really good, specific means for puffing out a
gene. The best thathad been done was to iso-
late chromosomes-to done from the chro-
mosomes. Ifyou have a chromosome-that's
100 million bases-you still have to clone
randomly," hesays.
Though the team's work has been met
with some surprise from other colleagues, the
fundamental concept behind it is not new,
Resnick says. He refers to that concept as the
"TAR phenomenon"-that multiple mole-
cules can be taken up by the yeast
Saccharomyces cerevisiae during transforma-
tion, andthat, iftheyhavehomology, orshare
identical sequences, then more than likely
those moleculeswill undergo recombination.
The team also based its experiments on
the knowledge that human DNA has
sequences that can function as origins ofrepli-
cation in yeast so that when human DNA is
combined with a plasmid lacking an origin,
an ardficial chromosome can be formed. The
size ofthe resulting pieces ofDNAdid, how-
ever, come as a surprise to the team. They
were able to retrieve pieces ofgenetic material
thatwere 100,000-700,000baseslong.
MappingtheMissingLinks
"The NIEHS team's discovery presents a
tool scientists will eventually use to fill in the
missing links in the human genome," says
Eric Green, chiefofthe genome technology
branch of the National Human Genome
Research Institute. Green, whose own
research has been dedicated to mapping and
sequencing human chromosomes, likens the
process ofmapping the genome to the orga-
nization of a large book that contains the
entire human genetic blueprint: "If you
know a few words on page 48 and a few
words on page 50, then here's a reliable
method to find out what's on page 49," he
says. "What theyhave done is isolate in a tar-
geted fashion [one] page," he explains. Using
this technique, scientists will be able to sys-
tematically fill in such "missing pages," and,
in the near future, "finish the human blue-
printvery, veryaccurately," Green claims.
Larionovpoints out the time and costsav-
ings advantages of using the TAR cloning
method over random sequencing. With this
new technique, he explains, "One person in
one lab can accomplish this in two weeks,
with no expensive equipment." This could
replace the costly and time-consuming work
of20-30 people. It could, Larionov says, save
millions ofresearchdollars.
RsechingtheGene-Disease Link
Besides filling gaps in the genome, the
techniquewill also aidscientists in the search
for disease-causing genes, according to Roger
H. Reeves, associate professor in the depart-
ment of physiology at Johns Hopkins
University School ofMedicine in Baltimore,
Maryland, who has conducted genetic
research on Down's syndrome and worked
on the Human Genome Project. "It allows
directed cloning of sequences from any
individual," Reeves says. "Yeast artificial
chromosome (YAC) library production is
extremely expensive, time-consuming, and
difficult," he explains. "It is not feasible to
make additional YAC libraries from a variety
of individuals, e.g., from each affected and
unaffected member ofapedigres-[a chart of
people within a family]-segregating a
disease gene." According to Reeves, this tech-
nique would, however, "allow cloning of
haplotypes [both the maternally and pater-
nally inherited chromosomes belonging to
an individual] containing mutant genes,
greatly facilitating the search for genes
responsible forhuman ... disease."
Resnick agrees that TAR cloning opens
the way to investigating genes and chromoso-
mal regions directlyfrom individuals. In such
clinical studies, only 10-20 ml ofa patient's
blood would be necessary to isolate a particu-
lar gene. Now Resnick, Larionov, and
Kouprina are investigating what they refer to
as the "TAR doning cycle," hoping to devel-
op a technique that would be useful in trans-
genics. In this series ofstudies, they are work-
ing to isolate a gene, then return it to mam-
malian cells, a method thatwould be portable
to other genetic diseases. In another study,
they are seeking to confirm the concept of
radial TAR doning, meaning that a gene can
be targeted even ifonly one sequence tag site
is known.
Lking Ahead
The ability to isolate the BRCA2gene in its
entirety will fuel further research into how
this gene functions-about which little is
known-as well as into the etiology ofcan-
cers associatedwith the gene. In future stud-
ies, the researchers hope to collaborate with
Barrett's group to isolate and transfer the
entire gene to tumor-derived human cell
lines where it is nonfunctional, and thus
facilitate a direct investigation into how the
gene functions under the influence of its
natural promoter. Eventually, the TAR
cloning method could be used to rapidly
clone mutant BRCA2 forms from DNA
extracted from clinical blood samples of
breast cancer families, and then test those
for function as well. So far, the team has iso-
lated and cloned several other key disease
genes as well, including the breast cancer
gene BRCAI, HPRT (a gene related to a
form ofretardation known as Lesch-Nyhan
syndrome), and rDNA (a group of genes
involved in enzymeproduction).
Investigators in three other NIEHS labo-
ratories are currently working to isolate more
genes, says Larionov, while four NIH labora-
tories are targeting stiU more. That makes a
total ofseven more clones in the works, but
Larionov won't be more specific, other than
to say that the genes are human disease genes.
With these sights in mind, Larionov has
already lined up several postdoctoral
researchers, including two from Japan, who
will join him in the NIEHS's new gene isola-
tion unit to pursue the next milestones on the
path to genediscoveries.
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